MaxCyte Stock

MaxCyte ROA

Delisted

The Return on Assets (ROA) of MaxCyte (MXCT) as of Jul 16, 2026 is -17.14 %. In the previous year, Return on Assets (ROA) was -14.14 % — a change of 21.28% (lower).

ROA

-17.14 %

YoY

21.28%

Last updated:

In 2026, MaxCyte's return on assets (ROA) was -17.14 %, a 21.28% increase from the -14.14 % ROA in the previous year.

Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

ROA Details

Understanding MaxCyte's Return on Assets (ROA)

MaxCyte's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing MaxCyte's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider MaxCyte's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in MaxCyte’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about MaxCyte stock

Return on Assets (ROA) of MaxCyte is -17.14 % in 2026.

Access this data via the Eulerpool API

Profitability — MaxCyte

All Key Metrics — MaxCyte